{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:15:29Z","timestamp":1772151329027,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.7759\/cureus.96601","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:24:02Z","timestamp":1762892642000},"source":"Crossref","is-referenced-by-count":1,"title":["Vedolizumab-Induced Interstitial Lung Disease: A Case of Delayed-Onset Pulmonary Toxicity"],"prefix":"10.7759","author":[{"given":"Tania","family":"Lasrado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qais","family":"Akasheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Enam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Entyvio\u00ae (vedolizumab). (2025). Accessed. July 26, 2025: https:\/\/www.entyvio.com\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch S","year":"2018","unstructured":"Skeoch S, Weatherley N, Swift AJ, et al.. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018, 7:356. 10.3390\/jcm7100356","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo P","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J. 2022, 60:2102776. 10.1183\/13993003.02776-2021","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel JF","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al.. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017, 66:839-851. 10.1136\/gutjnl-2015-311079","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i5.1716","article-title":"Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: a case report","volume":"10","author":"Zhang J","year":"2022","unstructured":"Zhang J, Liu MH, Gao X, Dong C, Li YX. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: a case report. World J Clin Cases. 2022, 10:1716-1722. 10.12998\/wjcc.v10.i5.1716","journal-title":"World J Clin Cases"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000627","article-title":"Vedolizumab-associated acute respiratory distress syndrome","volume":"25","author":"Nambiar S","year":"2018","unstructured":"Nambiar S, Karippot A, Oliver T. Vedolizumab-associated acute respiratory distress syndrome. Am J Ther. 2018, 25:e592-e593. 10.1097\/MJT.0000000000000627","journal-title":"Am J Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.016","article-title":"New-onset diffuse parenchymal lung disease in a 52-year-old woman with ulcerative colitis","volume":"158","author":"De Backer E","year":"2020","unstructured":"De Backer E, Bode H, Baert F. New-onset diffuse parenchymal lung disease in a 52-year-old woman with ulcerative colitis. Gastroenterology. 2020, 158:478-479. 10.1053\/j.gastro.2019.09.016","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002197","article-title":"Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis","volume":"33","author":"Rizos ED","year":"2021","unstructured":"Rizos ED, Antonogiannaki EM, Chatzidakis A, et al.. Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis. Eur J Gastroenterol Hepatol. 2021, 33:e1057-e1059. 10.1097\/MEG.0000000000002197","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13494","article-title":"Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis","volume":"47","author":"Cucinotta U","year":"2022","unstructured":"Cucinotta U, Dipasquale V, Costa S, Pellegrino S, Ramistella V, Romano C. Vedolizumab-associated pulmonary manifestations in children with ulcerative colitis. J Clin Pharm Ther. 2022, 47:254-256. 10.1111\/jcpt.13494","journal-title":"J Clin Pharm Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1056IM","article-title":"Necrobiotic pulmonary nodules of Crohn's disease in a patient receiving vedolizumab","volume":"199","author":"Myc LA","year":"2019","unstructured":"Myc LA, Girton MR, Stoler MH, Davis EM. Necrobiotic pulmonary nodules of Crohn's disease in a patient receiving vedolizumab. Am J Respir Crit Care Med. 2019, 199:e1-e2. 10.1164\/rccm.201806-1056IM","journal-title":"Am J Respir Crit Care Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.041","article-title":"Drug-related pneumonitis in patients receiving vedolizumab therapy for inflammatory bowel disease","volume":"20","author":"Pugliese D","year":"2022","unstructured":"Pugliese D, Privitera G, Schepis T, et al.. Drug-related pneumonitis in patients receiving vedolizumab therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022, 20:e1483-e1487. 10.1016\/j.cgh.2021.08.041","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432392-vedolizumab-induced-interstitial-lung-disease-a-case-of-delayed-onset-pulmonary-toxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:24:04Z","timestamp":1762892644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432392-vedolizumab-induced-interstitial-lung-disease-a-case-of-delayed-onset-pulmonary-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.96601","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}